Robert J. Alpern - 30 Sep 2023 Form 4 Insider Report for AbbVie Inc. (ABBV)

Role: Director
Signature: T.O. Odutayo, attorney-in-fact for Robert J. Alpern
Issuer symbol: ABBV
Transactions as of: 30 Sep 2023
Transactions value $: $7,453
Form type: 4
Filing time: 03 Oct 2023, 17:00:37 UTC
Previous filing: 11 Sep 2023
Next filing: 03 Jan 2024
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABBV	Stock Equivalent Units	Award	$7.45K	+50	+0.55%	$149.06	9.14K	30 Sep 2023	Common Stock	50	$149.06	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.
F2	Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

Content

Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.